500 Boylston Street, 11th Floor
Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin-4 (MC4) receptor agonist for the treatment of rare genetic disorders of obesity. Rhythm supports The Genetic Obesity Project(www.GeneticObesity.com), which is dedicated to improving the understanding of severe obesity that is caused by specific genetic defects. The company is based in Boston, Massachusetts.
Founder: Bart Henderson
CEO: Keith M. Gottesdiener
CMO: Fred T. Fiedorek
CSO: Lex H.T. Van der Ploeg
Please click here for clinical trial information.
75 articles with Rhythm
Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
Final protocol confirmed for pivotal Phase 3 clinical trial in pro-opiomelanocortin (POMC) deficiency obesity,
As of September 30, 2017, cash, cash equivalents and short-term investments were $30.4 million, as compared to $10.5 million as of December 31, 2016.
Rhythm Announces Preliminary Data from Phase II Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
The results are being presented at the ObesityWeek 2017 meeting held October 29 - November 2, 2017.
Pfizer has increased its stake in Rhythm Pharmaceuticals.
Rhythm Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters’ Option To Purchase Additional Shares
Rhythm And Camurus Announce Positive Initial Data For Extended-Release Delivery Of Setmelanotide For The Treatment Of Rare Genetic Disorders Of Obesity
Rhythm Expands Phase II Clinical Trials Of Setmelanotide To The Treatment Of Bardet-Biedl Syndrome Obesity
Rhythm Receives Expanded FDA Breakthrough Therapy Designation For Setmelanotide For Rare Genetic Disorders Of Obesity
Rhythm Announces "The Genetic Obesity Project" To Expand Understanding Of Rare Genetic Disorders Of Obesity
Rhythm Announces The New England Journal of Medicine Publication Of Setmelanotide Phase 2 Data For Treatment Of POMC Deficiency Obesity
Rhythm Receives Orphan Drug Designation For Setmelanotide For The Treatment Of Prader-Willi Syndrome